Involvement of myeloperoxidase gene polymorphism 463G>A in development of cervical squamous cell carcinoma.
The myeloperoxidase (MPO) -463G&gt;A (rs2333227) polymorphism has been linked with increased susceptibility to the development of various malignancies. However, the data on the association of the MPO -463G&gt;A transition with cervical cancer remain inconsistent. Using high resolution melting analysis we genotyped this polymorphism in women with cervical squamous cell carcinoma (SCC) (n = 476) and controls (n = 493) from a Polish Caucasian population. Logistic regression analysis was used to adjust for the effect of confounders such as age, parity, oral contraceptive use, tobacco smoking, and menopausal status, and revealed that the MPO -463G&gt;A single nucleotide polymorphism (SNP) was associated with an increased risk of SCC. The adjusted odds ratio (OR) for patients with the A/A genotype versus G/G genotype was 0.718 (95% CI 0.531-0.972, p = 0.0316). Stratified analyses between the MPO -463G&gt;A polymorphism and SCC risks demonstrated a protective role of the MPO -463G&gt;A SNP in patients with a positive history of parity and negative history of tobacco smoking. In patients with a positive history of parity, the age-adjusted OR for the A/A versus G/G genotype was 0.667 (95% CI 0.479-0.929, p = 0.0164). The age-adjusted OR for patients with a negative history of tobacco smoking for the A/A versus G/G genotype was 0.491 (95% CI 0.313-0.770, p = 0.0019). Our study demonstrated that the MPO -463G&gt;A SNP may protect from SCC in women from Polish Caucasian populations.